Hymecromone

Hymecromone

SCHEMBL2256610

COC.Cc1cc(=O)oc2cc(O)ccc12

nearest known ligand 0.90

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.90
KDM4E B2RXH2 9/20 0.90
HPGD P15428 6/20 0.90
GAA P10253 6/20 0.90
HSD17B10 Q99714 5/20 0.90
HSD17B3 P37058 5/20 0.90
GLA P06280 5/20 0.90
CA12 O43570 3/20 0.90
CA9 Q16790 3/20 0.90
CASP1 P29466 2/20 0.90
CASP7 P55210 2/20 0.90
AKR1B1 P15121 2/20 0.90
MCL1 Q07820 2/20 0.90
MAOB P27338 2/20 0.90
LMNA P02545 1/20 0.90
CYP1A2 P05177 1/20 0.90
CYP2C9 P11712 1/20 0.90
UGT1A1 P22309 1/20 0.90
KDR P35968 1/20 0.90
DYRK1A Q13627 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hymecromone SCHEMBL29364837 0.95 HSD17B3 (1.00) ALDH1A1KDM4EHPGDGAAHSD17B10
Hymecromone SCHEMBL24150 0.95 HSD17B3 (1.00) ALDH1A1KDM4EHPGDGAAHSD17B10
Hymecromone SCHEMBL29624431 0.95 HSD17B3 (1.00) ALDH1A1KDM4EHPGDGAAHSD17B10
Hymecromone SCHEMBL2357040 0.95 HSD17B3 (1.00) ALDH1A1KDM4EHPGDGAAHSD17B10
Hymecromone SCHEMBL31014 0.93 HSD17B3 (0.96) ALDH1A1KDM4EHPGDGAAHSD17B10
Hymecromone SCHEMBL27924142 0.93 HSD17B3 (0.96) ALDH1A1KDM4EHPGDGAAHSD17B10
Hymecromone SCHEMBL27728511 0.92 HSD17B3 (0.93) ALDH1A1KDM4EHPGDGAAHSD17B10
Hymecromone SCHEMBL7594956 0.89 KDM4E (0.87) ALDH1A1KDM4EHPGDGAAHSD17B10
Hymecromone SCHEMBL28882003 0.89 KDM4E (0.87) ALDH1A1KDM4EHPGDGAAHSD17B10
Hymecromone SCHEMBL720434 0.89 KDM4E (0.87) ALDH1A1KDM4EHPGDGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200188431-A1 GLUTAMINE DEHYDROGENASE INHIBITORS FOR USE IN MUSCLE REGENERATION KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2020-06-18 US claimed
EP-3635115-A1 GLUTAMINE DEHYDROGENASE INHIBITORS FOR USE IN MUSCLE REGENERATION VIB VZW (BE) 2020-04-15 EP claimed
WO-2018224636-A1 GLUTAMINE DEHYDROGENASE INHIBITORS FOR USE IN MUSCLE REGENERATION VIB VZW (BE) 2018-12-13 WO claimed
US-20200188431-A1 GLUTAMINE DEHYDROGENASE INHIBITORS FOR USE IN MUSCLE REGENERATION KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2020-06-18 US disclosed
EP-3635115-A1 GLUTAMINE DEHYDROGENASE INHIBITORS FOR USE IN MUSCLE REGENERATION VIB VZW (BE) 2020-04-15 EP disclosed
WO-2018224636-A1 GLUTAMINE DEHYDROGENASE INHIBITORS FOR USE IN MUSCLE REGENERATION VIB VZW (BE) 2018-12-13 WO disclosed
US-20180042899-A1 Method of Treating Transplant Rejection and Autoimmune Diseases NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-02-15 US disclosed
US-8772252-B2 Coumarin compounds as melanogenesis modifiers and uses thereof NEW YORK UNIVERSITY (US) 2014-07-08 US disclosed
US-20140050694-A1 Method of Treating Transplant Rejection and Autoimmune Diseases WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2014-02-20 US disclosed
US-8563754-B2 Compounds, compositions and methods for preventing skin darkening NEW YORK UNIVERSITY (US) 2013-10-22 US disclosed
US-20120220545-A1 COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF NEW YORK UNIVERSITY 2012-08-30 US disclosed
US-20110190229-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING NEW YORK UNIVERSITY 2011-08-04 US disclosed
US-20090269772-A1 SYSTEMS AND METHODS FOR IDENTIFYING COMBINATIONS OF COMPOUNDS OF THERAPEUTIC INTEREST THERASIS, INC. 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220545-A1 COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF TYR, MC1R, MITF ALDH1A1 246/4885KDM4E 79/4885HPGD 2055/4885
US-20200188431-A1 GLUTAMINE DEHYDROGENASE INHIBITORS FOR USE IN MUSCLE REGENERATION GLUL, GLS2, GLS ALDH1A1 312/4885KDM4E 864/4885HPGD 150/4885
US-20110190229-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING TYR, MC1R, MITF ALDH1A1 397/4885KDM4E 274/4885HPGD 574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.